Rainier Acquisition Corporation Announces Pricing of $75,000,000 Initial Public Offering

Rhea-AI Summary

Rainier Acquisition Corporation (Nasdaq: RNAQU/RNAQ/RNAQW) priced its initial public offering of 7,500,000 units at $10.00 per unit, for expected gross proceeds of $75,000,000 before underwriting discounts and expenses. Each unit consists of one Class A ordinary share and one-quarter of one redeemable warrant, with each whole warrant exercisable at $11.50 per share.

The units are expected to begin trading on the Nasdaq Capital Market under the symbol RNAQU on August 27, 2026, with the Class A shares and warrants later trading separately under RNAQ and RNAQW. The offering is expected to close on August 28, 2026, subject to customary conditions. Rainier is a special purpose acquisition company targeting global life sciences sectors and has granted the underwriter, Chardan, a 45-day option to purchase up to an additional 1,125,000 units at the IPO price to cover over-allotments. A registration statement was declared effective by the SEC on August 26, 2026.

Positive

• $75,000,000 in expected gross IPO proceeds at $10.00 per unit
• Potential additional capital from underwriter’s 45-day option for 1,125,000 units
• Planned listing on Nasdaq Capital Market with symbols RNAQU, RNAQ, RNAQW
• Defined life sciences focus for future business combination targets

Negative

• None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Rainier Acquisition Corporation (the "Company") announced today that it priced its initial public offering of 7,500,000 units consisting of one Class A ordinary share and one-quarter of one redeemable warrant at a price of $10.00 per unit. The offering is expected to generate gross proceeds of $75,000,000 before underwriting discounts and offering expenses. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. No fractional warrants will be issued upon separation of the units, and only whole warrants will trade. The units are expected to be listed on The Nasdaq Capital Market and trade under the ticker symbol "RNAQU" beginning August 27, 2026. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on The Nasdaq Capital Market under the symbols "RNAQ" and "RNAQW," respectively. The offering is expected to close on August 28, 2026, subject to customary closing conditions.

The Company is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its search on the global life sciences industries, including therapeutics, diagnostics, genomics, precision medicine, life science tools, research services, biomanufacturing, and related subsectors, although its efforts to identify a prospective target business will not be limited to any particular industry or geographical region. The Company's management team is led by Gbola Amusa, MD, CFA, Chief Executive Officer, and Guy Barudin, Chief Financial Officer.

Chardan is acting as the sole book-running manager for the offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 1,125,000 units at the initial public offering price to cover over-allotments, if any.

The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained from Chardan, 1 Pennsylvania Plaza, Suite 4800, New York, New York 10119, or by email at: prospectus@chardan.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the "SEC") on August 26, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any State or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State or jurisdiction.

Cautionary Note Concerning Forward-Looking Statements
This press release contains statements that constitute "forward-looking statements," including with respect to the anticipated closing of the offering and the Company's search for an initial business combination. No assurance can be given that the offering will be completed on the terms described, or at all, or that the proceeds of the offering will be used as indicated.

Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement for the initial public offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:
Gbola Amusa, Chief Executive Officer
1 Pennsylvania Plaza, Suite 4800
New York, NY 10119
Tel.: (646) 465-9000
gamusa@rainier-acq.com

FAQ

What are the key terms of the Rainier Acquisition (NASDAQ: RNAQ) IPO priced on August 26, 2026?

Rainier Acquisition priced 7,500,000 units at $10.00 per unit for expected gross proceeds of $75,000,000. Each unit includes one Class A ordinary share and one-quarter of one redeemable warrant, with each whole warrant exercisable at $11.50 per share, according to the company.

When will Rainier Acquisition units, shares, and warrants start trading on Nasdaq and under which tickers (RNAQ, RNAQU, RNAQW)?

According to Rainier Acquisition, its units are expected to begin trading on the Nasdaq Capital Market under ticker RNAQU on August 27, 2026. Once separated, the Class A ordinary shares and warrants are expected to trade under symbols RNAQ and RNAQW, respectively.

What does the Rainier Acquisition (RNAQ) SPAC intend to focus on after its IPO?

Rainier Acquisition intends to pursue a business combination in the global life sciences industries. According to the company, this includes therapeutics, diagnostics, genomics, precision medicine, life science tools, research services, biomanufacturing, and related subsectors, though it is not limited to any industry or geographic region.

What are the warrant terms in the Rainier Acquisition (RNAQW) IPO units?

Each IPO unit contains one-quarter of one redeemable warrant, with each whole warrant allowing purchase of one Class A ordinary share at $11.50. According to Rainier Acquisition, no fractional warrants will be issued and only whole warrants will trade once the securities separate.

Who is managing the Rainier Acquisition (RNAQ) IPO and what over-allotment option was granted?

Chardan is acting as sole book-running manager for the Rainier Acquisition offering. According to the company, the underwriter has a 45-day option to buy up to an additional 1,125,000 units at the IPO price to cover any over-allotments.

When is the Rainier Acquisition (RNAQ) IPO expected to close and what regulatory approval has it received?

The offering is expected to close on August 28, 2026, subject to customary closing conditions. According to Rainier Acquisition, a registration statement for these securities was declared effective by the SEC on August 26, 2026, enabling the IPO.